ALOX12 and metabolic dysfunction-associated steatotic liver disease: Recent studies have shown that ALOX12–12-HETE pathway was activated both in liver IRI and NASH, but whether ALOX12–12-HETE pathway was activated during IRI in NAFLD remains unknown.